Equillium, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 8, 2023. Equillium is a clinical-stage biotechnology company developing treatments for autoimmune and inflammatory diseases. Its candidates include EQ101, EQ102 and itolizumab (EQ001). The company reported no product sales, royalties or milestone revenue; reported revenue came from its agreement with Ono Pharmaceutical.
Financial highlights
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $8.9m | $0 | $26.9m | $0 |
| Research and development expense | $9.0m | $8.8m | $27.9m | $29.0m |
| General and administrative expense | $3.5m | $4.5m | $10.3m | $12.0m |
| Operating loss | $(3.6)m | $(13.2)m | $(11.3)m | $(64.1)m |
| Net loss | $(3.7)m | $(13.7)m | $(11.0)m | $(65.2)m |
| Net loss per share | $(0.11) | $(0.40) | $(0.32) | $(1.95) |
| Operating cash flow | Not separately presented | Not separately presented | $(16.1)m | $(36.5)m |
- Revenue under the Ono asset purchase agreement comprised development funding and recognition of the upfront payment: $6.7m and $2.2m, respectively, in Q3; $20.1m and $6.8m, respectively, year to date. No revenue was recognized in the 2022 comparison periods.
- At September 30, cash and cash equivalents were $34.4m and short-term investments were $11.9m, totaling $46.3m. Total assets were $55.2m, liabilities $31.1m and stockholders’ equity $24.1m. Accumulated deficit was $183.4m.
- Cash and cash equivalents fell $24.7m from year-end 2022. Investing activities provided $0.8m, primarily reflecting investment maturities net of purchases. Financing activities used $9.3m, including $9.1m to repay the term loan and $0.3m for share repurchases.
- The company prepaid and terminated its loan agreement in May 2023; it reported no notes payable or remaining obligations under that agreement at September 30. Q3 interest expense was zero; nine-month interest expense was $0.5m.
- Q3 and nine-month income tax expense was $0.5m and $0.6m, respectively, primarily attributed to domestic cash taxes. The filing reports a full valuation allowance against net deferred tax assets.
Margins are not a useful operating measure in this period: Equillium has no product sales, and reported revenue is collaboration and development funding rather than product revenue.
Material changes versus the prior comparable period
- Revenue increased from zero in 2022 due to the Ono agreement. The company recognized $26.9m in the first nine months of 2023.
- Nine-month net loss narrowed to $11.0m from $65.2m, primarily because 2022 included $23.0m of acquired in-process R&D expense for the Bioniz asset acquisition and had no Ono revenue. Nine-month operating expenses were $38.2m versus $64.1m.
- Nine-month R&D expense decreased $1.2m, although clinical development costs rose $3.3m; Australian research tax incentives, lower employee costs and reduced non-clinical costs partly offset that increase. G&A expense fell $1.7m.
- Cash used in operating activities improved to $16.1m from $36.5m, reflecting Ono development funding and a higher Australian tax incentive benefit. The company also used cash to repay its loan, eliminating debt.
Outlook, commentary and risks
- Management expects September 30 cash, cash equivalents and short-term investments, after the repurchase program, to fund currently planned operations into 2025. The liquidity note separately states that resources are expected to fund operations for at least 12 months from the filing date. These are management estimates, dependent on assumptions and subject to change.
- Management expects expenses and losses to continue and R&D spending to increase as it advances EQ101, EQ102 and, if Ono does not exercise its option, itolizumab. Product revenue is not expected in the next 12 months, if ever; additional financing may be needed and may be dilutive or unavailable on acceptable terms.
- Under the Ono agreement, Equillium received a $26.4m upfront payment and quarterly development funding; it had received $31.3m in development funding by September 30. Ono may pay approximately $33.3m if it exercises its option and up to $101.4m in potential development and commercialization milestones. Exercise and milestone payments are uncertain. The option period is tied to EQUALISE lupus nephritis topline data and interim EQUATOR aGVHD data.
- Clinical milestones described in the filing include expected EQ102 healthy-volunteer data in Q4 2023, initial EQ101 alopecia areata data in Q4 2023 and EQ101 topline data in mid-2024, and an EQUATOR interim review in 2024. The filing also reports November 2023 EQUALISE Type B results: 6 of 15 subjects achieved complete response and 5 of 15 partial response at week 28; topline data were planned for Ono in early 2024. These post-quarter results are preliminary clinical information, not financial-period results.
- In October 2023, the company established a Jefferies at-the-market facility for up to $6.34m of common stock; no shares had been sold under it as of filing. A board-authorized repurchase program permits up to $7.5m through December 31, 2024; $0.3m had been used by September 30.
- Key risks include clinical-trial safety, efficacy, enrollment and timing; dependence on Ono funding and its option decision; need for additional capital; manufacturing and CRO reliance; competition; and potential Nasdaq delisting. The company had until April 1, 2024 to regain compliance with the $1.00 minimum bid-price requirement. Management said disclosure controls were effective; no material change in internal control over financial reporting was reported. No legal proceedings were reported.
Important facts for investors to verify
- Whether cash burn, trial spending and the assumptions behind management’s stated runway into 2025 remain consistent with the liquidity estimate.
- Ono’s continued development funding, option status and timing of the EQUALISE and EQUATOR data that govern the option period.
- Clinical data, trial progress and safety updates for EQ101, EQ102 and itolizumab, including whether preliminary results are confirmed in final analyses.
- Any ATM share sales, further stock repurchases, dilution and progress toward Nasdaq minimum-bid compliance.
- Potential obligations under the Bioniz acquisition and Biocon license, including contingent milestone payments and royalties not recorded as current debt.